UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2023

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-37348 (Commission File Number) 46-4348039 (IRS Employer Identification No.)

500 River Ridge Drive Norwood, Massachusetts (Address of Principal Executive Offices)

02062 (Zip Code)

Registrant's Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	
Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	CRBP	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Corbus Pharmaceuticals Holdings, Inc. (the "Company") updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.	Description
99.1	Investor Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date: November 14, 2023

By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer

Exhibit 99.1



Connecting Innovation to Purpose

Corporate Presentation November 2023

NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma

Forward-Looking Statements

This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identi ed by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our nancial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's lings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of mew information. The Company undertakes no obligation to publicly update any forward-looking stateme


All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

A diversified pipeline with differentiated clinical risk profiles

CRB-701 Next generation Nectin-4 targeting ADC	CSPCDose Escalation(China)Started Q1 2023 Ends Q4 2023		Dose Confirmation / Expansion Start Q12024			
	solid tumors	Corbus (US + Europe)	Dose Escalation Planned start Q1 2024 End Q2 2024	Dose Confirmation / Expansion Start Q3 2024		
Anti-Integrin mAb						
CRB-601 Anti-ανβ8 mAb (<i>TGFβ-targeting</i>) ανβ8 enriched solid tumors		IND Q4 2023				
Highly peripherally-restricted CB1R inverse agonist						
CRB-913 CB1R inverse agonist Obesity and related conditions		IND Q4 2024				

CRB-701 Next Gen Nectin-4 Targeting ADC

4





Latest Padcev® Q3 revenues¹

	Three	months en	ded Sept	ember 30,	Nine m	onths ende	d Septer	nber 30,
(dollars in millions)	2023	2022	% Chan	ige	2023	2022	% Cha	nge
Total Net Product Sales	\$ 571	\$ 428	33	%	\$ 1,583	\$ 1,243	27	%
ADCETRIS	\$ 246	\$ 219	13	%	\$ 751	\$ 601	25	%
PADCEV	\$ 200	\$ 105	89	%	\$ 479	\$ 329	46	%
TUKYSA	\$ 102	\$88	16	%	\$ 289	\$ 267	8	%
TIVDAK	\$ 23	\$ 16	40	%	\$ 64	\$ 45	42	%


22nd October 2023 ²

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer




Sources: 1. SGEN Q3 earnings report, 2. SGEN press release, October 2023, 3. Evaluate Pharma

PADCEV[®] Global Projected Revenues in UC/Bladder³













WARNING: SERIOUS SKIN REACTIONS

- PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.
 Closely monitor patients for skin reactions.
 Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.
 Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions *[see Dosage and Administration (2,2), Warnings and Precautions (5,1)]*.
- Reactions (6.1)].


A Black Box warning for PADCEV[®] cautions physicians regarding the skin toxicity risk¹

Greater than 25% of PADCEV® discontinuations are linked to peripheral neuropathy³

PADCEV® Adverse Events (% of patients)

		PADCEV [®] monotherapy ¹					
		All Grades	\geq Gr 3	All Grades	\geq Gr 3		
	Skin Reactions	56%	12%	67%	16%		
	Sensory Peripheral Neuropathy	53%	5%	59%	4.3%		
	Motor Peripheral Neuropathy	NR	NR	10%	2.7%		
NF	NR = not reported						

Similar dose limiting toxicities seen across divergent ADCs that share same constellation of 'linker + payload' Val-Cit linker + vedotin (MMAE) payload




 $Padcev \ Val-Cit \ linker + payload = mc-VC-PABC = Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl \ alcohol \ p-nitrophenyl \ carbonate$

Source(s): 1.Fu et al., Science, 2023 doi: 10.1016/j.iscl.2023.107778. Padcev® Prescribing information, Adcetris @ Prescribing Information, Tivdak @ Pescribing Information, Polivy @ Prescribing Information. Shi et al., 2022 https://doi.org/10.1080/10717544.2022.2069883



Monotherapy Padcev®





Real-world use, dose intensity, and adherence to Padcev®

Metric	Result (N = 416)	
EV use		
Number of cycles (median, IQR)	5 (2,8)	
EV dose intensity		
Treatments per patient month (mean [SD])	2.6 [0.6]	
Dosing frequency; treatments per cycle (mean [SD])	2.4 [0.5]	
Dose (mean, mg/kg [SD])	1.1 [0.2]	
Change in average dose (mg) from baseline (%)	-9.6 [20.2] %	
EV treatment adherence		
Received on average > 2 treatments per cycle (%)	58.8 [34.4] %	


	→ Seagen [®] → astellas	Bicycle	Mobwell 迈威生物
Limitation	Padcev®	BT8009	9MW-2821
Upper dose limit	1.25 mg/kg ¹	5 mg/m^2 ⁴	1.25 mg/kg ³
Schedule	D1, D8, D15 /28 days	Q1W	D1, D8, D15 /28 days
≥ Grade 3 AE rate	51% (n=155) ²	65% (n=20) ⁶	35% (n=85) ³
Peripheral Neuropathy	38%	30%	17%
Skin reactions	25%	10%	18%
Neutropenia (Gr 3)	5% ³	10%#	19%
Dose reduction	34%	16%	3.5%
Dose interruptions	64%	24%	28%

1 Rosenberg, et al., "EV-101 JCO, 2020 Apr 1; 38(10): 1041–1049, 2. Powles et al., EV-301 2021, 3. Zhang et al., ESMO 2023, 4 Rigby et al., 2023, 6 Bicycle corporate deck Nov 2023 # - combined frequency of Grade 3 neutropenia/ low neutrophil count







Source(s): Modified image from Corbus data on file; Corbus data on file





Comparisons of payload in plasma across $Padcev \ensuremath{\mathbb{R}}$ and CRB-701






Proprietary insights are driving indication selection for CRB-701







Source: Corbus data on file, Swiecicki et al., Abstract 6017., ASCO 2023

Clinical Status: Non-clinical / Clinical Development plan










But...

Muscle loss

Tolerability

Accessibility

-Long-term compliance is ~ 27%



Source(s): RBC report Oct 2023

23

Muscle loss: Degree of weight loss – Quality of weight loss

Tolerability: Single MOA – Multiple orthogonal MOAs


Accessibility: Injectables – Oral small molecules

Source(s): RBC report Oct 2023


CB1 inverse agonism: The return of a clinically-validated obesity drug class

The CB1 MOA is clinically validated in obesity: data from 1st gen drugs





Source(s): <u>1.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després et al. NEJM. Nov 2005.</u> 2. A clinical trial assessing the safety and efficacy of taranabant, a CBIR inverse agonist, in obese and overweight patients: a high-dose study. Aronne et al. Nature, Feb 2010.




Novo Nordisk acquisition of Inversago marks return of CB1 as an MOA in obesity



Novo acquires Inversago for up to \$1 billion, spotlighting troubled weight loss approach

Aug. 10, 2023



CRB-913: oral CB1 inverse agonist for combination therapy with incretins

OBESITY SYMPOSIUM Obesity Biology and Integrated Physiology

Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutide in the diet-induced obesity mouse model


Marshall Morningstar 🥺 | Andrew Kolodziej | Suzie Ferreira | Tracy Blumen | Rachael Brake | Yuval Cohen

Nov. 2023

28


X

Design goals:




CRB-913 is the outcome of a multi-year medicinal chemistry campaign






CRB-913: marked peripheral restriction vs. rimonabant in both lean and obese mice





Brain concentration (ng/g)					
single acute dose	CRB-913 (lean mice)	INV-202 (lean mice)	fold difference		
10 mg/Kg	26	319	1:12		

Source(s): Morningstar et al 2023 and Liu et al 2021


CRB-913: similar weight loss vs rimonabant at same daily doses in DIO mice








Source(s): Morningstar et al 2023




(Similar effect also seen when CRB-913 was combined with liraglutide)

Source(s): Company data on file.







Leptin measured at Day 28 of treatment


.


Source(s): 1Leptin and the maintenance of elevated body weight, Pan and Myers, Nature Reviews, Jan 2018. Company data on file.


The Role of Leptin

- The hormone leptin regulates food
 intake
- Normally, leptin signals satiety (feeling "full")
- In obesity, resistance to leptin develops and hunger persists despite high leptin levels ("leptinemia")
- A reduction in leptin levels is believed to be important for weight loss¹

CRB-913 reduces liver fat alone and in combination with semaglutide or tirzepatide







Leadership Financials Upcoming catalysts

42

Management Team



Yuval Cohen, PhD Chief Executive Officer, Director

Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005.



Rachael Brake, PhD Chief Scientific Officer

Expert in developing and executing innovative drug discovery and clinical development oncology programs at several leading pharmaceutical companies.



Sean Moran, CPA, MBA Chief Financial Officer

Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies.



Christina Bertsch Head of Human Resources

Accomplished senior human resource executive providing strategic HR consulting services to both large and small businesses across a variety of industries

Board of Directors





Amb. Alan Holmer Ret. Chairman of the Board

More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA.



Rachelle Jacques

More than 25-year professional career, experience in U.S. and global biopharmaceutical commercial leadership, including multiple high-pro le product launches in rare diseases; CEO of Akari Therapeutics. (NASDAQ: AKTX)



Anne Altmeyer, PhD, MBA, MPH Director

20 years of experience advancing oncology R&D programs and leading impactful corporate development transactions; currently President & CEO of TigaTx.



John K. Jenkins, MD Director

Distinguished 25-year career serving at the U.S. FDA, including 15 years of senior leadership in CDER and OND.



Avery W. (Chip) Catlin Director

More than 25 years of senior nancial leadership experience in life science companies; Former CFO and Secretary of Celldex Therapeutics.



Pete Salzmann, MD, MBA Director

20 years of industry experience and currently serves as Chief Executive Of cer of Immunovant (NASDAQ: IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases.



Yuval Cohen, PhD Chief Executive Officer, Director


Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005.



Yong (Ben) Ben, MD, MBA Director

25 years of oncology R&D experience across industry and academia. Held two industry CMO positions, most recently at BeiGene (BGNE).

2023 - 2024 Catalysts



Focus on developing precision oncology + differentiated assets



 $\label{eq:clinically} Clinically developing a next generation Nectin-4 targeting ADC$



Move CRB-913 into clinic with IND in H2 2024



Advancing anti- $\alpha\nu\beta8$ integrin program to IND submission in Q4 2023



\$29 Million

ash, cash equivalents and investments as of September 30, 2023 4.4M Common Shares Outstanding (5.2M Fully-Diluted Shares)



Appendix



CRB-601 Potential "best-in-class" ανβ8 mAb

Novel mechanism to target $\text{TGF}\beta$ in the tumor microenvironment




Focus on adopting a precision-targeted approach



Large opportunity potential if POC is validated

Targeting the integrin α v β 8 represents a novel approach to regulating TGF β




CRB-601 is targeting latent -TGF β by blocking the integrin $\alpha v\beta 8$

The integrin $\alpha v \beta 8$ is expressed in the tumor microenvironment (TME)

Latent-TGF β is also expressed in the TME

CRB-601 is a blocking antibody preventing the interaction of these two proteins




mAbs targeting TGF β activation are advancing clinically

		P fizer	Scholar Rock.	abbvie	Roche
	CRB-601	PF-06940434	SRK-181	ABBV-151	RG6440
MOA	ανβ8	ανβ8	L-TGFB	GARP (TGFβ1)	L-TGFB
Clinical Stage	IND in Q4 2023	Phase 1/2 updated July 2023	Phase 1	Phase 2 updated July 2023	Phase 1
Indications	Solid Tumors	Solid Tumors	Solid Tumors	Solid Tumors	Solid Tumors
Туре	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody
ROA	IV	IV	IV	IV	IV




Source(s): Company websites. Clinicaltrials.gov. Internal analysis.


CRB-601 enhances anti-PD-1 therapy in checkpoint inhibition sensitive and resistant murine tumor models



Blockade of $\alpha\nu\beta8$ in combination with anti-PD-1 increased TIL populations in immune excluded EMT6 tumors



CRB-601 Reshapes the landscape of effector T and NK cells in MC38 tumors



Applying a proprietary algorithm to define the clinical focus for CRB-601




A multi-parametric, immune-focused algorithm has refined indications for **CRB-601**

The combination of immune features and gene expression profiles have identified 9 indications for clinical priority


Source(s): Corbus proprietary analysis


Clustered Tumor Types High Quartiles

Low



Prioritization of indications with differential gene expression vs. normal tissues will emphasize focus on the tumor potential of $\alpha v \beta 8$





Development of a NEW patient enrichment biomarker will assist in enriching for responses and addressing the right immune resistant patient population with CRB-601

Source(s): Corbus proprietary analysis: Log2 fold change of Nectin-4 expression as a ratio to normal tissue

CRB-601 Next Steps

- IND filing scheduled for H2-2023
- FPI expected H1-2024
- Non-clinical validation of a potential patient selection biomarker in 2023
- Dose escalation and confirmation will be the focus through 2024